Cardiac Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 18.41 Billion
CAGR (2026-2031)	8.01%
Fastest Growing Segment	BillionP and NT-proBillionP
Largest Market	North America
Market Size (2031)	USD 29.23 Billion

Market Overview

The Global Cardiac Biomarkers Market will grow from USD 18.41 Billion in 2025 to USD 29.23 Billion by 2031 at a 8.01% CAGR. Cardiac biomarkers are measurable proteins or enzymes released into the bloodstream during cardiac stress, serving as essential indicators for diagnosing conditions such as myocardial infarction. The market is primarily driven by the rising prevalence of cardiovascular disorders and the critical need for rapid diagnostic accuracy in emergency settings. This demand is underscored by significant disease burden statistics; according to the American Heart Association, in 2024, approximately 126.9 million adults in the United States were estimated to have some form of cardiovascular disease. Such high prevalence rates necessitate widespread adoption of diagnostic testing, continuously fueling market revenue.

A primary challenge hindering market expansion is the stringent regulatory approval process required for new diagnostic assays. Manufacturers must navigate complex compliance standards and lengthy validation phases to demonstrate clinical utility, which significantly increases development costs and delays product launches. Furthermore, inconsistent reimbursement coverage for novel biomarkers across global healthcare systems can restrict commercial adoption and limit the financial viability of testing solutions for emerging providers.

Key Market Drivers

The escalating global prevalence of cardiovascular diseases acts as a fundamental catalyst for the cardiac biomarkers market, creating sustained demand for diagnostic testing. As the incidence of conditions such as myocardial infarction and heart failure rises, healthcare providers increasingly rely on sensitive biomarkers for rapid triage and effective risk stratification. This surge in disease burden directly correlates with higher testing volumes across hospital and clinical settings, necessitating robust diagnostic infrastructure. According to the Centers for Disease Control and Prevention, June 2025, in the 'Vital Statistics Rapid Release' report, the number of deaths attributed to heart disease in the United States increased to 683,037 in 2024. Such mortality statistics highlight the critical necessity for accurate tools to manage the growing patient population and mitigate severe outcomes.

Technological breakthroughs in high-sensitivity biomarker assays are simultaneously expanding market capabilities by enhancing diagnostic precision. These advanced solutions allow for the detection of cardiac troponin at significantly lower concentrations, facilitating the identification of myocardial injury much earlier than conventional methods. This evolution supports a transition toward more proactive patient management and improved clinical outcomes. The market's positive response to these innovations is reflected in financial performance; according to Abbott, October 2024, in the 'Third-Quarter 2024 Results' press release, global Core Laboratory Diagnostics sales increased 4.5 percent on an organic basis, driven by the adoption of updated diagnostic systems. Reinforcing this broader trend of high-volume utilization, according to Roche, in 2025, the company delivered a total of 30 billion diagnostic tests to customers worldwide during the preceding fiscal year.

Download Free Sample Report

Key Market Challenges

The stringent regulatory approval process functions as a substantial barrier that directly hampers the growth of the Global Cardiac Biomarkers Market. Manufacturers must navigate intricate compliance frameworks and conduct extensive validation phases to demonstrate the clinical utility of new diagnostic assays. This rigorous scrutiny necessitates prolonged development timelines and results in significantly higher operational costs before a product can even reach commercialization. Consequently, the high financial and time investment required to secure approvals often deters companies from introducing innovative biomarkers, which ultimately slows the pace of innovation and restricts the entry of advanced diagnostic solutions into the market.

The impact of these regulatory burdens is evident in recent industry trends showing a strategic retreat from markets with complex compliance requirements. According to MedTech Europe, in 2024, the selection of the European Union as the priority region for first product launches by large in vitro diagnostic manufacturers declined by 40 percent due to the challenges associated with the new regulatory environment. This statistic underscores how heavy regulatory demands force companies to divert resources and delay launch strategies. By stalling the introduction of essential diagnostic tools, these regulatory challenges effectively constrain revenue opportunities and limit the broader commercial expansion of the sector.

Key Market Trends

The Advancement of Automated High-Throughput Immunoassay Systems is significantly reshaping the Global Cardiac Biomarkers Market as clinical laboratories prioritize workflow efficiency to manage escalating testing volumes. Manufacturers are increasingly commercializing integrated platforms that combine clinical chemistry and immunodiagnostics, thereby reducing manual intervention and shortening turnaround times for critical cardiac assays. This robust demand for advanced diagnostic infrastructure is evident in recent industry performance; according to Roche, January 2025, in the 'Roche reports strong 2024 results with 7% sales growth' press release, the company's Diagnostics Division base business sales increased 8 percent at constant exchange rates, driven by the sustained uptake of immunodiagnostic solutions and the introduction of the cobas Mass Spec system.

A Shift Toward Personalized Medicine and Value-Based Cardiac Care is simultaneously influencing market dynamics, compelling healthcare providers to adopt diagnostic protocols that minimize unnecessary resource utilization. By leveraging high-precision biomarkers for rapid risk stratification, hospitals can effectively rule out acute cardiac events, alleviating emergency department overcrowding and reducing overall healthcare costs. This trend toward improved operational outcomes is supported by recent data; according to GlobalRPH, October 2025, in the 'High-Sensitivity Troponin Testing: The End of Unnecessary Chest Pain Admissions?' article, the implementation of high-sensitivity cardiac troponin I testing protocols resulted in an absolute decrease of 5.6 percent in hospital admissions for chest pain.

Segmental Insights

The BNP and NT-proBNP segment represents the fastest-growing category within the Global Cardiac Biomarkers Market, driven primarily by the escalating global prevalence of heart failure. Leading regulatory and clinical authorities, such as the European Society of Cardiology, strongly recommend these natriuretic peptides as the gold standard for diagnostic and prognostic risk stratification in acute care settings. This robust clinical endorsement, combined with the increasing adoption of high-sensitivity point-of-care testing solutions, is accelerating the segment's expansion and enabling clinicians to make timely, evidence-based therapeutic decisions.

Regional Insights

North America maintains a dominant position in the global cardiac biomarkers market due to the high prevalence of cardiovascular diseases and a strong focus on early disease diagnosis. This leadership is supported by a well-established healthcare infrastructure and the concentrated presence of major market players. Additionally, extensive awareness initiatives regarding heart health by organizations such as the American Heart Association drive the demand for diagnostic testing. Favorable product approvals and regulatory guidelines from the U.S. Food and Drug Administration further reinforce the region's market expansion and adoption rates.

Recent Developments

• In April 2025, Roche received the CE Mark for its Chest Pain Triage algorithm, a digital diagnostic solution within its navify portfolio. The algorithm was developed to assist emergency department clinicians in rapidly ruling in or ruling out myocardial infarction by integrating high-sensitivity cardiac troponin T results with the timing of blood sampling. By automating the interpretation of complex biomarker data according to European Society of Cardiology guidelines, the tool aimed to accelerate patient triage and reduce unnecessary hospital wait times. This certification facilitated the immediate rollout of the software to healthcare providers across the European Union and other accepting markets.
• In January 2025, bioMérieux announced that it had entered into an agreement to acquire SpinChip Diagnostics, a Norwegian medical device company, for a total enterprise value of NOK 1,624 million. This strategic acquisition granted bioMérieux full ownership of a novel point-of-care immunoassay platform capable of delivering high-sensitivity cardiac biomarker results from whole blood in approximately ten minutes. The transaction was intended to bolster the company’s diagnostic offerings in emergency and critical care settings, complementing its existing portfolio with technology that combines central laboratory performance with the speed required for acute triage.
• In October 2024, Siemens Healthineers secured FDA clearance for a new prognostic application of its Atellica IM High-Sensitivity Troponin I (TnIH) test. This regulatory milestone allowed the assay to be used for predicting the risk of death or major adverse cardiac events in patients presenting with symptoms of acute coronary syndrome. The expanded indication enabled clinicians to stratify patient risk for up to one year following the initial presentation, providing a valuable tool for long-term management. The approval highlighted the company's focus on leveraging established biomarkers to deliver deeper clinical insights for high-risk cardiac populations.
• In May 2024, Beckman Coulter announced that it had received clearance from the U.S. Food and Drug Administration for its Access NT-proBNP assay to be used on the DxI 9000 Immunoassay Analyzer. The newly cleared assay was designed to provide rapid results in under 11 minutes to aid in the diagnosis of heart failure and the risk stratification of patients with acute coronary syndrome. This development expanded the menu of cardiac tests available on the company’s high-throughput platform, aiming to enhance laboratory workflow efficiency and support timely clinical decision-making for patients presenting with cardiac symptoms.

Key Market Players

• Abbott Laboratories Inc.
• QuidelOrtho Corporation
• Siemens Healthineers AG
• F. Hoffmann-La Roche Ltd
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Randox Laboratories Ltd.
• Creative Diagnostics
• Life Diagnostics Inc.
• BIOMÉRIEUX Inc.

By Type	By Application	By Region
Troponin CK-MB Myoglobin BNP and NT-proBNP Others	Acute Coronary Syndrome Myocardial Infarction Congestive Heart Failure Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cardiac Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cardiac Biomarkers Market, By Type:

• Troponin
• CK-MB
• Myoglobin
• BNP and NT-proBNP
• Others

• Cardiac Biomarkers Market, By Application:

• Acute Coronary Syndrome
• Myocardial Infarction
• Congestive Heart Failure
• Others

• Cardiac Biomarkers Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE